Presenter: Lindsay Davies, PhD, Chief Scientific Officer, NextCell Pharma

Advancing mesenchymal stromal cell (MSC) therapies require greater consistency in starting material, manufacturing inputs, and development strategies. Variability in donor sources, isolation methods, and culture conditions can introduce heterogeneity that slows translational processes. Addressing these challenges increasingly requires collaboration across the therapy ecosystem.  

In this discussion Lindsay Davies, from NextCell Pharma, will explore how strategic partnerships can help address these challenges. By aligning MSC sources with scalable culture media and reliable supply chains, collaborative approaches may support standardized research workflows, reduce development risk, and help accelerate the path from discovery to clinical translation.

Learn how to:  

• Identify sources of variability impacting MSC research and development  
• Evaluate how strategic collaborations can help close the gaps across MSC development  
• Access the role of standardized MSC starting materials in improving experimental reproducibility  
• Recognize how ecosystem partnerships support scalable manufacturing and translational progress